TrialLeukemia2026

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Fausto Castagnetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.